Safety and Immunogenicity of a Second Dose of an Investigational Maternal Trivalent Group B Streptococcus Vaccine in Nonpregnant Women 4–6 Years After a First Dose: Results From a Phase 2 Trial

BACKGROUND: Maternal immunization against group B streptococcus (GBS) could protect infants from invasive GBS disease. Additional doses in subsequent pregnancies may be needed. We evaluated the safety and immunogenicity of a second dose of an investigational trivalent CRM(197)-glycoconjugate GBS vac...

Descripción completa

Detalles Bibliográficos
Autores principales: Leroux-Roels, Geert, Bebia, Zourab, Maes, Cathy, Aerssens, Annelies, De Boever, Fien, Grassano, Luca, Buffi, Giada, Margarit, Immaculada, Karsten, Annette, Cho, Stephen, Slobod, Karen, Corsaro, Bartholomew, Henry, Ouzama
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286364/
https://www.ncbi.nlm.nih.gov/pubmed/31394574
http://dx.doi.org/10.1093/cid/ciz737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286364/
https://www.ncbi.nlm.nih.gov/pubmed/31394574
http://dx.doi.org/10.1093/cid/ciz737

Ejemplares similares